Life Sciences Voice Top Five Newsletter
Welcome to the latest edition of the Life Sciences Voice Top Five Newsletter, your source for the top developments in the life sciences industry! This week, we take a look at Takeda entering a...
View ArticleEuropean Regulatory Agency Gives AstraZeneca’s Covid-19 Preventative Drug...
Despite having exited the COVID-19 vaccine market this year, pharma giant AstraZeneca has launched its COVID-19 prevention drug, which has received the green light from the European regulatory agency....
View ArticleSanofi’s Dupixent Injectable Approved by the EU to Treat Chronic Lung Disease
Sanofi and Regeneron gained approval from the European Union for expanded use of the Dupixent injection in patients suffering from chronic lung disease- a rare instance where the EU authorizes a...
View ArticleDeal on Cancer ADC Gets Canceled by Eisai and Bristol Myers
Eisai will terminate a partnership on a dual-action lung and ovarian cancer medication with Bristol Myers Squibb, the organization declared on Monday. Bristol Myers Squibb, the U.S. drugmaker that...
View ArticleRoche Stops Lung Cancer Immunotherapy Trial in Newest Disappointment
The management of Roche has decided to stop the immunotherapy treatment trial for lung cancer, which is a further blow to making a breakthrough in cancer treatment. They stated that this decision was...
View ArticlePentixapharm Acquires Glycotope for its target discovery business
In a bid to amp up its radiopharmaceuticals pipeline, Pentixapharm has chosen to acquire Glycotope’s target discovery business, which focuses on preclinical antibodies directed against several oncology...
View ArticleMyricx Bio Raises $114M in Series A Funding to Advance NMTi-ADCs Development
Antibiotic-drug conjugates (ADCs) are a highly competitive biologics segment. The strategic development of these molecules has drawn the attention of the largest pharmaceutical companies in China....
View ArticleBeacon Raises $170M Series B For Eye Disease Candidates
Beacon Therapeutics has secured $170 million in Series B funding, which the gene therapy company plans to utilize for advancing its eye disease candidates through clinical trials. Established in...
View ArticleAfter a Two-Year Recall, Roche Set to Relaunch Eye Implant Medication Susvimo
Susvimo was halted by Roche in mid-2022 due to manufacturing issues that prompted a market recall. Now, the therapy can be back on the market as the FDA has permitted the resumption of the treatment....
View ArticleMesoblast Resubmits BLA For Ryoncil Approval
The globally recognized allogeneic cellular therapy developer, Mesoblast Limited, has resubmitted its BLA for the approval of Ryoncil to treat children with SR-aGVHD. Following further evaluation, the...
View ArticleScorpion Secures $150M in Series C Funding to Expand Cancer Pipeline Clinical...
Scorpion Therapeutics has raised $150M to strengthen its clinical pipeline by advancing most of its small molecule oncology programs. Founded in Boston, the biotech company applies a sophisticated drug...
View ArticleHouse Committee Orders FDA to Halt Regulation Governing Lab-Developed Tests
The FDA has been instructed by lawmakers to halt the implementation of its final regulation related to laboratory-developed tests (LDTs). The proposal for funding that the FDA and other government...
View ArticleSionna Pens Deal With AbbVie For Cystic Fibrosis Drugs
Sionna Therapeutics has swiftly found a way to put part of its $182 million series C haul to use by signing a contract with AbbVie to add three clinical-phase prospects to its growing pipeline of...
View ArticleMeilleur Technologies, Creator of PET Tests for Alzheimer’s Disease, Acquired...
With the acquisition of Meilleur Technologies, Lantheus is expanding its portfolio of PET imaging agents for Alzheimer’s disease. Under the terms of the agreement, Meilleur’s radiopharmaceutical...
View ArticleCovid Symptoms Prevented by New Drug Used on Mice, No Risk of Resistance
Research findings from new studies show that organ damage resulting from Covid-19 can be averted by an antioxidant enzyme that shields a cell’s mitochondria. The study was led by a devoted team of...
View ArticleBacked by Novo Holdings, Asceneuron Raises $100 Million in Quest for...
Alzheimer’s drugs have been flooding the market lately, as investors look for the next big advance in the field of neuroscience. Novo Holdings aims to achieve this by injecting $100 million in Series C...
View ArticleAutoimmune-Stricken Patients Respond to Allogeneic CAR-T Treatment
Three patients with autoimmune disorders have responded favorably to allogeneic CAR-T therapy, marking a breakthrough for the “off-the-shelf” cell therapy technology. According to experts at William...
View ArticleBrazil Curbs Poultry Exports Amid Newcastle Viral Disease
Brazil has restricted its exports of chicken meat and eggs to 44 nations after the Newcastle virus disease was discovered on a farm in the state of Rio Grande do Sul. The ban, validated by the Ministry...
View ArticleIonis Plans to Advance Angelman drug Biogen with clinical success
Ionis Pharmaceuticals is set to advance one of its drugs for Angelman syndrome to the third trial phase after proving its efficacy in an earlier trial. Angelman syndrome is a rare genetic disorder that...
View ArticleClik here to view.
AstraZeneca Grows EGFR Portfolio with $45M Pinetree Deal
Pinetree Therapeutics, a biotechnology firm focused on developing targeted protein degraders (TPD) to combat drug resistance in oncology treatment, announced it has entered into an exclusive option and...
View Article